45 related articles for article (PubMed ID: 38720458)
1. Multivalent Aptamer-Functionalized Single-Strand RNA Origami as Effective, Target-Specific Anticoagulants with Corresponding Reversal Agents.
Krissanaprasit A; Key CM; Froehlich K; Pontula S; Mihalko E; Dupont DM; Andersen ES; Kjems J; Brown AC; LaBean TH
Adv Healthc Mater; 2021 Jun; 10(11):e2001826. PubMed ID: 33882195
[TBL] [Abstract][Full Text] [Related]
2. Genetically Encoded, Functional Single-Strand RNA Origami: Anticoagulant.
Krissanaprasit A; Key C; Fergione M; Froehlich K; Pontula S; Hart M; Carriel P; Kjems J; Andersen ES; LaBean TH
Adv Mater; 2019 May; 31(21):e1808262. PubMed ID: 30972819
[TBL] [Abstract][Full Text] [Related]
3. A high affinity, antidote-controllable prothrombin and thrombin-binding RNA aptamer inhibits thrombin generation and thrombin activity.
Bompiani KM; Monroe DM; Church FC; Sullenger BA
J Thromb Haemost; 2012 May; 10(5):870-80. PubMed ID: 22385910
[TBL] [Abstract][Full Text] [Related]
4. A DNA origami-based aptamer nanoarray for potent and reversible anticoagulation in hemodialysis.
Zhao S; Tian R; Wu J; Liu S; Wang Y; Wen M; Shang Y; Liu Q; Li Y; Guo Y; Wang Z; Wang T; Zhao Y; Zhao H; Cao H; Su Y; Sun J; Jiang Q; Ding B
Nat Commun; 2021 Jan; 12(1):358. PubMed ID: 33441565
[TBL] [Abstract][Full Text] [Related]
5. Increased anticoagulant activity of thrombin-binding DNA aptamers by nanoscale organization on DNA nanostructures.
Rangnekar A; Zhang AM; Li SS; Bompiani KM; Hansen MN; Gothelf KV; Sullenger BA; LaBean TH
Nanomedicine; 2012 Jul; 8(5):673-81. PubMed ID: 21889476
[TBL] [Abstract][Full Text] [Related]
6. A functional RNA-origami as direct thrombin inhibitor with fast-acting and specific single-molecule reversal agents in vivo model.
Krissanaprasit A; Mihalko E; Meinhold K; Simpson A; Sollinger J; Pandit S; Dupont DM; Kjems J; Brown AC; LaBean TH
Mol Ther; 2024 May; ():. PubMed ID: 38720458
[TBL] [Abstract][Full Text] [Related]
7. Specific antidotes in development for reversal of novel anticoagulants: a review.
Gomez-Outes A; Suarez-Gea ML; Lecumberri R; Terleira-Fernandez AI; Vargas-Castrillon E
Recent Pat Cardiovasc Drug Discov; 2014; 9(1):2-10. PubMed ID: 25494843
[TBL] [Abstract][Full Text] [Related]
8. New parenteral anticoagulants: focus on factor Xa and thrombin inhibitors.
Ahrens I; Bode C
Curr Drug Discov Technol; 2012 Jun; 9(2):129-36. PubMed ID: 21838659
[TBL] [Abstract][Full Text] [Related]
9. Polyvalent nucleic acid aptamers and modulation of their activity: a focus on the thrombin binding aptamer.
Musumeci D; Montesarchio D
Pharmacol Ther; 2012 Nov; 136(2):202-15. PubMed ID: 22850531
[TBL] [Abstract][Full Text] [Related]
10. Current Strategies for the Management of Bleeding Associated with Direct Oral Anticoagulants and a Review of Investigational Reversal Agents.
Kaide CG; Gulseth MP
J Emerg Med; 2020 Feb; 58(2):217-233. PubMed ID: 31831187
[TBL] [Abstract][Full Text] [Related]
11. Dabigatran etexilate--a novel, reversible, oral direct thrombin inhibitor: interpretation of coagulation assays and reversal of anticoagulant activity.
van Ryn J; Stangier J; Haertter S; Liesenfeld KH; Wienen W; Feuring M; Clemens A
Thromb Haemost; 2010 Jun; 103(6):1116-27. PubMed ID: 20352166
[TBL] [Abstract][Full Text] [Related]
12. Direct-Acting Oral Anticoagulants and Their Reversal Agents-An Update.
Kustos SA; Fasinu PS
Medicines (Basel); 2019 Oct; 6(4):. PubMed ID: 31618893
[No Abstract] [Full Text] [Related]
13.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
